The Royal Orthopaedic Hospital, NHS Foundation Trust, Bristol Road South, Northfield, Birmingham, B31 2AP, UK.
Department of Orthopedics, HUS Peijaksen sairaala, P.O. Box 900, 00029 HUS, Vantaa, Finland.
J Orthop Surg Res. 2021 Jan 9;16(1):35. doi: 10.1186/s13018-020-02192-6.
Whilst bony fixation of hip replacement has stable solutions, there remains controversy over which bearing best optimizes longevity and function. Ceramic-on-ceramic (CoC) bearing combinations are associated with lower risk of revision due to aseptic loosening and dislocation. Evidence for long-term functional outcomes of modern, 4th generation CoC bearings is limited. The aim of this study was to analyze outcomes and complications of the R3™ Acetabular System (Smith & Nephew, Inc., Cordova, TN, USA) in combination with BIOLOX® Delta ceramic femoral head in patients undergoing primary total hip arthroplasty (THA).
Between June 2009 and May 2011, 175 patients (178 hips) were enrolled into a prospective, study at 6 sites in Europe and prospectively followed-up at 3 months and 1, 3, 5, and 7 years postoperative.
Total WOMAC score improved from 63 (range, 22-91) preoperative to 8 (range, 0-8) at 1-year follow-up and remained unchanged at 7-year follow-up. Modified Harris hip score improved from 45 (range, 10-87) preoperative to 83 (range, 25-100) at 3 months, 91 (range, 42-100) at 1 year, and 92 (range, 46, 100) at 7 years. UCLA Activity Rating Scale score improved from 3.3 (range, 1-8) preoperative to 6.2 (range, 2-8) at 1 year; it marginally declined to 5.8 (range, 3-8) at 7-year follow-up. There were 4 trochanteric fractures and 5 patients died of unrelated reasons. Three hips were revised (2 periprosthetic fractures and 1 subluxation). The 7-year cumulative survival rate was 98.3%.
Clinical and functional improvements of THA with CoC bearing are maintained at 7 years postoperative.
ClinicalTrials.Gov, NCT03566082 , Registered 10 January 2018-retrospectively registered.
虽然髋关节置换的骨固定有稳定的解决方案,但哪种轴承能最好地优化寿命和功能仍存在争议。陶瓷对陶瓷(CoC)轴承组合与无菌性松动和脱位相关的翻修风险较低。关于现代第四代 CoC 轴承的长期功能结果的证据有限。本研究的目的是分析 R3™髋臼系统(Smith & Nephew,Inc.,田纳西州科多瓦)与 BIOLOX®Delta 陶瓷股骨头联合应用于初次全髋关节置换术(THA)患者的结果和并发症。
2009 年 6 月至 2011 年 5 月,在欧洲的 6 个地点进行了一项前瞻性研究,共纳入 175 例患者(178 髋),并在术后 3 个月、1 年、3 年、5 年和 7 年进行前瞻性随访。
WOMAC 总评分从术前的 63(范围:22-91)改善至术后 1 年的 8(范围:0-8),7 年随访时无变化。改良 Harris 髋关节评分从术前的 45(范围:10-87)改善至术后 3 个月的 83(范围:25-100)、术后 1 年的 91(范围:42-100)和术后 7 年的 92(范围:46,100)。UCLA 活动评分从术前的 3.3(范围:1-8)改善至术后 1 年的 6.2(范围:2-8);7 年随访时略有下降至 5.8(范围:3-8)。有 4 例转子间骨折和 5 例患者因其他原因死亡。3 髋翻修(2 例假体周围骨折和 1 例半脱位)。7 年累积生存率为 98.3%。
CoC 轴承 THA 的临床和功能改善可维持至术后 7 年。
ClinicalTrials.Gov,NCT03566082,2018 年 1 月 10 日注册-回顾性注册。